Possibilities for active immunotherapy of human cancer.
Hellström
K E
KE
Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121.
Hellström
I
I
D000943:Antigens, Differentiation / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000276:immunology*; D000957:Antigens, Viral, Tumor / Q000276:immunology; D000939:Epitopes; D006649:Histocompatibility Antigens / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins / Q000276:immunology; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
D000943:Antigens, Differentiation; D000951:Antigens, Neoplasm; D000957:Antigens, Viral, Tumor; D000939:Epitopes; D006649:Histocompatibility Antigens; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins; C029237:tumor-associated transplantation antigen